-

ANAPLAN, INC. INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Continues to Investigate Anaplan, Inc.’s Buyout by Thoma Bravo LP – PLAN

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors it is investigating whether the directors of Anaplan, Inc. (“Anaplan”) (NASDAQ: PLAN) breached their fiduciary duties to its shareholders in approving a buyout with Thoma Bravo LP (“Thoma Bravo”) for inadequate consideration. If you are an Anaplan shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982, or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether Anaplan’s board of directors failed to maximize the value of Anaplan for the benefit of Anaplan’s shareholders in connection with its announced buyout by Thoma Bravo, in breach of their fiduciary duties to Anaplan’s shareholders, and whether Anaplan’s shareholders have suffered damages as a result.

On March 20, 2022, Anaplan announced it had reached an agreement to be bought out by Thoma Bravo for $66.00 per share, in an all-cash transaction valued at $10.7 billion.

What You Can Do

If you are an Anaplan shareholder, you may have legal claims against Anaplan’s directors. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
844-818-6982
jpettigrew@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:PLAN

Release Versions

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
844-818-6982
jpettigrew@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Hub Group, Inc. (NASDAQ: HUBG)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Hub Group is a transport...

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against PomDoctor, Ltd. (NASDAQ: POM)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants PomDoctor Ltd., Zhenyang Shi, Li Xu, Cogency Global, Joseph Stone Capital, LLC, and Marcum Asia CPAs, LLP (collectively, the “Defendants”). The action, which was filed in the U.S. District Court for the Southern District of New York and captioned Louie v. PomDoctor Ltd. et al., Ca...

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY) breached their fiduciary duties to Eli Lilly and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Eli Lilly’s board of directors or senior management failed to manage Eli Lilly in an acceptable manner, in breach of their fid...
Back to Newsroom